Drug intelligence / Profile preview

GNL-NM-MGH003

Development stage: Preclinical
Lead developer: Genencell
Modality: Small Molecules

Overview

GNL-NM-MGH003 is a natural product-based drug candidate being developed by the South Korean biotechnology company Genencell for the treatment of kidney failure. As a natural product medicine (천연물 의약품), it is derived from biological sources. While the specific botanical origin and molecular targets have not been publicly disclosed, the candidate is part of a pipeline focused on leveraging natural extracts for various therapeutic indications. It is currently in early-stage development, with the company conducting efficacy trials and preparing for or conducting domestic clinical studies in South Korea.

Beyond the preview

Go deeper on GNL-NM-MGH003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNL-NM-MGH003.

Explore the full profile